[{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Brinzolamide","moa":"||Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.35999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.35999999999999999,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alcon Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Prairie Eye Center","sponsor":"Sengi","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Prairie Eye Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Prairie Eye Center \/ Sengi","highestDevelopmentStatusID":"11","companyTruncated":"Prairie Eye Center \/ Sengi"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alcon Inc \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Brinzolamide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
